Trial · NCT05239221
Adverse events1,488
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,488
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Palpitations | Cardiac disorders | Part A (Cohort A1, 5 ug Dose) | 0 | 3 | 0 |
| other | Palpitations | Cardiac disorders | Part A (Cohort A2, 10 ug Dose) | 0 | 6 | 0 |
| other | Palpitations | Cardiac disorders | Part A (Cohort A3, 20 ug Dose) | 0 | 6 | 0 |
| other | Palpitations | Cardiac disorders | Part A (Cohort A4, 40 ug Dose) | 0 | 6 | 0 |
| other | Palpitations | Cardiac disorders | Part A (Cohort A5, 60 ug Dose) | 0 | 6 | 0 |
| other | Palpitations | Cardiac disorders | Part A (Cohort A6, 120 ug Dose) | 1 | 6 | 1 |
| other | Palpitations | Cardiac disorders | Part A (Cohort A7, 90 ug Dose) | 0 | 6 | 0 |
| other | Palpitations | Cardiac disorders | Part A (Placebo) | 1 | 13 | 1 |
| other | Palpitations | Cardiac disorders | Part B (Cohort B1, 10 ug Doses) | 0 | 8 | 0 |
| other | Palpitations | Cardiac disorders | Part B (Cohort B2, 20 ug Doses) | 1 | 8 | 1 |
| other | Palpitations | Cardiac disorders | Part B (Cohort B3, 40 ug Doses) | 0 | 10 | 0 |
| other | Palpitations | Cardiac disorders | Part B (Cohort B4, 60 ug Doses) | 1 | 8 | 1 |
| other | Palpitations | Cardiac disorders | Part B (Cohort B5, 80 ug Doses) | 0 | 8 | 0 |
| other | Palpitations | Cardiac disorders | Part B (Placebo) | 0 | 10 | 0 |
| other | Palpitations | Cardiac disorders | Part C (Cohort C1, Starting Dose of 20 ug/Day) | 1 | 12 | 1 |
| other | Palpitations | Cardiac disorders | Part C (Cohort C2, Starting Dose of 10 ug/Day) | 0 | 16 | 0 |
| other | Motion Sickness | Ear and labyrinth disorders | Part A (Cohort A1, 5 ug Dose) | 0 | 3 | 0 |
| other | Motion Sickness | Ear and labyrinth disorders | Part A (Cohort A2, 10 ug Dose) | 0 | 6 | 0 |
| other | Motion Sickness | Ear and labyrinth disorders | Part A (Cohort A3, 20 ug Dose) | 0 | 6 | 0 |
| other | Motion Sickness | Ear and labyrinth disorders | Part A (Cohort A4, 40 ug Dose) | 0 | 6 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05239221/events